A Phase 1, Non-randomized, Open-label, Parallel-group Single-dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Intravenous Rivipansel (Pf-06460031) In Subjects With Moderate Hepatic Impairment And In Healthy Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Rivipansel (Primary)
- Indications Sickle cell anaemia
- Focus Pharmacodynamics
- Sponsors Pfizer
- 18 Apr 2017 Status changed from recruiting to completed.
- 18 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Mar 2017.
- 21 Dec 2016 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.